Serum concanavalin-A binding in rheumatoid arthritis

Area of Science:

• Immunology
• Clinical Chemistry
• Rheumatology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation.
• Monitoring disease activity and treatment response in RA is crucial for patient management.
• Existing serological markers for acute phase proteins can be complex or costly.

Purpose of the Study:

• To evaluate a nephelometric assay for concanavalin-A binding of serum acute phase proteins (con-A binding) as a marker of disease activity in rheumatoid arthritis (RA).
• To assess the correlation of con-A binding with other established acute phase reactants.
• To determine the utility of con-A binding in monitoring treatment response to D-penicillamine in RA patients.

Main Methods:

• A nephelometric assay was used to measure con-A binding in serum samples from RA patients.
• Con-A binding levels were compared with clinical assessments, blood viscosity, and C-reactive protein (CRP) levels.
• Twenty-four RA patients were treated with D-penicillamine for six months, with serial clinical and serological assessments.

Main Results:

• Con-A binding showed a strong correlation with blood viscosity, CRP, and other acute phase reactants in patients with active RA.
• Clinical improvement following D-penicillamine treatment was associated with significant reductions in both CRP and con-A binding.
• Serological changes, specifically in con-A binding, did not always parallel clinical improvements in individual patients.

Conclusions:

• The nephelometric assay for con-A binding is a viable and potentially valuable tool for assessing disease activity in rheumatoid arthritis.
• This assay demonstrates good correlation with established markers and shows promise in monitoring therapeutic interventions.
• The simplicity and cost-effectiveness of this assay make it an attractive option for routine clinical use in RA management.